S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
$6.54
-1.5%
$7.54
$4.00
$8.53
$464.47M1.68449,770 shs293,256 shs
IMRIS Inc. stock logo
IMRSQ
IMRIS
$0.00
$0.00
$0.00
N/AN/AN/AN/A
SCIE
SpectraScience
$0.00
$0.00
$0.00
$497K0.32N/AN/A
ULGX
Urologix
$0.00
$0.00
$0.00
N/A0.07N/AN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
-1.51%-6.84%-14.62%+10.10%+49.66%
IMRIS Inc. stock logo
IMRSQ
IMRIS
0.00%0.00%0.00%0.00%0.00%
SCIE
SpectraScience
0.00%0.00%0.00%0.00%0.00%
ULGX
Urologix
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
3.6748 of 5 stars
2.05.00.03.12.73.30.6
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/AN/AN/AN/AN/AN/AN/A
SCIE
SpectraScience
N/AN/AN/AN/AN/AN/AN/AN/A
ULGX
Urologix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
2.00
Hold$7.7518.50% Upside
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/AN/AN/A
SCIE
SpectraScience
N/AN/AN/AN/A
ULGX
Urologix
N/AN/AN/AN/A

Current Analyst Ratings

Latest CGNT, ULGX, IMRSQ, and SCIE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$5.00 ➝ $8.00
4/10/2024
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$5.00 ➝ $7.50
4/9/2024
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
$313.40M1.48N/AN/A$3.12 per share2.10
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/AN/AN/AN/AN/A
SCIE
SpectraScience
N/AN/AN/AN/AN/AN/A
ULGX
Urologix
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
-$15.57M-$0.23N/AN/AN/A-4.97%-12.06%-5.57%6/20/2024 (Estimated)
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/A0.00N/AN/AN/AN/AN/AN/A
SCIE
SpectraScience
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ULGX
Urologix
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
N/AN/AN/AN/AN/A
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/AN/AN/AN/A
SCIE
SpectraScience
N/AN/AN/AN/AN/A
ULGX
Urologix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
N/A
1.39
1.26
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/AN/AN/A
SCIE
SpectraScience
N/AN/AN/A
ULGX
Urologix
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
72.92%
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/A
SCIE
SpectraScience
N/A
ULGX
Urologix
N/A

Insider Ownership

CompanyInsider Ownership
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
62.70%
IMRIS Inc. stock logo
IMRSQ
IMRIS
N/A
SCIE
SpectraScience
0.50%
ULGX
Urologix
8.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cognyte Software Ltd. stock logo
CGNT
Cognyte Software
1,61371.02 million26.49 millionOptionable
IMRIS Inc. stock logo
IMRSQ
IMRIS
121N/AN/ANot Optionable
SCIE
SpectraScience
54.97 billion4.94 billionNot Optionable
ULGX
Urologix
61N/AN/ANot Optionable

CGNT, ULGX, IMRSQ, and SCIE Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cognyte Software logo

Cognyte Software

NASDAQ:CGNT
Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company also offers network intelligence analytics, open source and threat intelligence analytics, and operational intelligence analytics solutions. Its solutions are designed to support various use cases and support a range of users, including data analysts, investigation managers, and security operations center operators, as well as operational field teams. In addition, the company provides customer support, professional, and integration services. Its government customers include national, regional, and local government agencies; and enterprise customers consist of commercial and physical security customers. Cognyte Software Ltd. was incorporated in 2020 and is headquartered in Herzliya, Israel.
IMRIS logo

IMRIS

OTCMKTS:IMRSQ
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

SpectraScience

OTCMKTS:SCIE
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

Urologix

OTCMKTS:ULGX
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.